Program
AOC 1020
A development code. Also written as “AOC-1020”.
In Novartis's pipeline, siRNA DUX4 knockdown
. Its studies are mostly in Muscular Dystrophy, Facioscapulohumeral, led by Novartis.
Furthest: phase 3, since Jun 13, 20253 company-led studies, 2 open or runningNext primary completion: May 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 32 open or running | phase 3since Jun 13, 2025 | Feb 17, 2023 | May 2028phase 3 · NCT07038200 |
- Named in Novartis’s own pipeline as
DWH213 (del-brax)
, phase 3, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 17, 2023First study: phase 2 study in Muscular Dystrophy, FacioscapulohumeralFirst studyNCT05747924 · 90 enrolled · United States, Canada, United Kingdom
- Aug 7, 2024Phase 2 study in Muscular Dystrophy, FacioscapulohumeralNCT06547216 · 84 enrolled · United States, Canada, United Kingdom
- Jun 13, 2025Phase 3 study in Muscular Dystrophy, FacioscapulohumeralNCT07038200 · 200 planned · United States, Canada, Denmark and more
Ahead
- May 2028Primary completion: phase 3 study in Muscular Dystrophy, FacioscapulohumeralNCT07038200
- Apr 2030Primary completion: phase 2 study in Muscular Dystrophy, FacioscapulohumeralNCT06547216
TargetBeta
“siRNA DUX4 knockdown”the company's pipeline, read by Claude · source
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07038200Muscular Dystrophy, Facioscapulohumeral · United States, Canada, Denmark and more | 3 | Recruiting | May 2028 | 200 |
| NCT06547216Muscular Dystrophy, Facioscapulohumeral · United States, Canada, United Kingdom | 2 | Active, not recruiting | Apr 2030 | 84 |
| NCT05747924Muscular Dystrophy, Facioscapulohumeral · United States, Canada, United Kingdom | 2 | Completed | Mar 18, 2026 | 90 |
How it is read
Names in the registry
- “AOC 1020”, 2 entries
- “AOC-1020”, 1 entry
Codes read as this program: AOC1020.
Conditions, from the studies’ own filings
- Muscular Dystrophy, Facioscapulohumeral, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.